Menu
Enrolling by invitation NCT07568470

Can the Phoenix Sign be Elicited With D5W

No phase Interventional Drop Foot

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Infiltration of D5W.
Who it may be relevant to
Registry conditions: Drop Foot. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Elicitation of the Phoenix Sign With Non-guided Subcutaneous D5W Infiltration

Overview

To determine if the Phoenix sign can be reliably elicited with non-guided subcutaneous infiltration of D5W (5% Dextrose in Water) in patients with subclinical weakness of the extensor hallucis longus (EHL) muscle.

Detailed description

* To determine the prevalence of subclinical EHL weakness in a general clinical population * To measure the time course of strength changes following D5W infiltration * To identify potential predictive factors for positive response to treatment

Interventions

  • Drug Infiltration of D5W
    There is no other intervention.

Primary outcome measures

  • Changes in motor strength of dorsiflexion of the anterior and lateral compartments of the lower extremity [Time frame: From enrollment to end of their treatment at 1 day]
  • Presence of absence of increase in motor strength of the lower extremity in dorsiflexion [Time frame: From enrollment to the end of the day]
  • Number of subjects that have increased dorsiflexion strength after D5W infiltration [Time frame: Enrollment to end of clinic vist in 1 hour]

Eligibility criteria

Inclusion criteria

  • subjects must have a weakness of dorsiflexion and specifically of the Extensor Hallucis Longus muscle
  • drop foot

Exclusion criteria

  • Trypanaphobia
  • allergy to D5W

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Sequential
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 1 center
  • US Neuropathy Centers — Marietta

Identifiers

NCT: NCT07568470 · USNC

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗